 |
||||||||||
|
The Myeloma Institute Treats Multiple Myeloma Patients From All Over the World The Myeloma Institute is an international leader in the treatment and study of multiple myeloma and related diseases and one of the largest referral centers in the world. With a team of dynamic scientists and clinicians, the Myeloma Institute translates advances in the laboratory to novel clinical treatments. The hallmark of the Myeloma Institute is a program of clinical trials that challenge the traditional body of thought on disease treatment in order to improve outcomes. Superior clinical outcomes have been achieved at the Myeloma Institute through the "Total Therapy" approach, incorporating upfront tandem transplants. Outcomes have improved through the years with the incorporation of new agents such as thalidomide and bortezomib for consolidation and salvage therapies. Click here for graphs. Click here for a presentation on Treatment Approach at the Myeloma Institute. MIRT utilizes information from Gene Array Analysis for patient management and planning of therapy. The Myeloma Institute recently reported our Total Therapy outcome data at the annual ASCO meeting in Chicago. Results indicated that Total Therapy 3 (TT3) had improved results in the 85% of patients with low-risk myeloma, as defined by gene expression profiling (GEP). Thus, at 4 years from start of protocol therapy, 85% are estimated to be alive and 80% event-free; of the 70% entering complete remission (CR), almost 90% remain in CR at 4 years. This contrasts with less than one-half of the 15% with high-risk myeloma for these 3 endpoints. We concluded from these data, as also portrayed in Dr. Barlogie's presentation (see below), that it will be difficult to improve upon TT3 in low-risk disease, while high-risk patients need to have a substantive change in treatment direction. Consequently, we are now entering a new era of risk-adapted therapy using our very robust GEP predictive model. Click here to read more about the data and our conclusions. Click here for The Myth of Incurability, Dr. Bart Barlogie’s 2008 ASCO meeting presentation. ***** MYELOMA IN THE NEWS ***** Thalidomide Continues to Show Benefits Against Myeloma UAMS Performs Record 7,000th Myeloma Stem-Cell Transplant Click here for the story. For 10 years, artist Cathy Joyce has been cancer-free. But she still takes life one day a time Myeloma Patients Flock to Little Rock Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure? Recent Publications from the Myeloma Institute
Two Myeloma Institute researchers have received 2007 Fellow Awards from the Multiple Myeloma Research Foundation Igor Entin, Ph.D., Instructor James Stewart, Ph.D., Instructor Listen to presentations from Myeloma Institute faculty at the June 2007 XIth International Myeloma Workshop: John Shaughnessy, PhD Joshua Epstein, DSc Bart Barlogie, MD, PhD, Our specialized and experienced staff provides
|
 Ines Plog of Hamburg, Germany - Myeloma Institute for Research and Therapy patient, diagnosed Sept. 23, 2003, came to MIRT in December, 2003. In remission since May, 2005. |
||||||||
|
Having problems
with the site? E-mail the Webmaster.
The information on the Myeloma Institute web site
is not intended as a substitute for professional medical attention. The
information is intended only as an aid in understanding current medical
knowledge. A physician should always be consulted for any health concern or
medical condition. The Myeloma Institute web site provides links to other
organizations as a service to our readers. The Myeloma Institute is not
responsible for the information provided on other web sites. |
||||||||||
